24/7 Wall St. noted that Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) Duchenne muscular dystrophy treatment eteplirsen was superior to competing products. The stock price leaped $7.29 to close at $33.36.
Sarepta Therapeutics has superior product
November 20, 2015 at 16:51 PM EST